Exabis Library
Welcome to the e-CCO Library!
P408: Switching from infliximab originator to a biosimilar does not affect efficacy, pharmacokinetics and immunogenicity in paediatric patients with inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P409 Endoscopic and histological activity is associated with non-response to biologic therapy in ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P409: FMT induced increase in gut microbial diversity and Clostridia is associated with clinical response in patients with ulcerative colitis – results from STOP Colitis trial
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P409: Impact of biological therapy in postoperative morbidity in elective surgical resections in Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P409: Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: Results from a real-world observational study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P409: Mesalamine enemas for induction of remission in pediatric ulcerative colitis refractory to oral mesalamine: a prospective cohort study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P409: Non-invasive predictors of maintaining remission in patients with moderately to severely active Ulcerative Colitis treated with tofacitinib who dose-reduced from tofacitinib 10 mg twice daily to 5 mg twice daily: 6-month data from the double-blind, randomised RIVETING study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P409: Non-medical reverse switch between the originator infliximab and its biosimilar in patients with inflammatory bowel disease: clinical outcomes and therapeutic drug monitoring
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P409: Using antidepressants for refractory symptoms of Inflammatory Bowel Disease: a prospective service evaluation
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P410 Could the disease become ‘a friend’? The mediating role of illness acceptance on self-efficacy and quality of life of gastroenterological patients
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P410: Extraintestinal manifestations and quality of life in patients with ulcerative colitis: 1-year data from ICONIC
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P410: Has body composition any effect on thiopurine level in IBD?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P410: Long-term persistence and safety of biological drugs in patients with Inflammatory Bowel Disease. Differences between women and men: SEXEII study of ENEIDA
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P410: safety of biological drugs for inflammatory bowel disease in elderly patients
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P410: Segmental endoscopic scoring improves outcome prediction in acute severe colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P410: Vedolizumab is safe and effective for IBD, but has no effect on liver biochemistry in patients with concurrent PSC
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P410: Which patients with established Crohn's disease benefit most from the use of the Patency capsule test prior to small bowel capsule endoscopy?
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P411 Faecal calprotectin is more tightly associated with endoscopic disease activity compared with other biomarkers in patients with inflammatory bowel disease under maintenance treatment with adalimumab
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P411: Baseline Hypertrophy of the Submucosa at intestinal ultrasound predicts Failure of Treatment in patients with ulcerative colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P411: Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease centre: Accessibility, resource utilisation and outcomes
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM